Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
In elderly patients with locally advanced esophageal squamous cell carcinoma, neoadjuvant immunochemoradiotherapy offers superior tumor response but increases surgical complexity and cardiac risks compared to immunochemotherapy. Personalize
Shorter diagnosis-to-treatment intervals independently predict worse outcomes in follicular lymphoma treated with immunochemotherapy, highlighting a novel prognostic factor beyond existing risk indices.
Two contemporary series show that SMARCA4‑altered NSCLC is molecularly and clinically heterogeneous: squamous tumors have high pathologic responses to neoadjuvant immunochemotherapy, while non‑squamous tumors—especially those with co‑occurr
The ENRICH trial demonstrates that ibrutinib combined with rituximab significantly improves progression-free survival compared to standard immunochemotherapy in older patients with untreated mantle cell lymphoma, heralding a new chemotherap